Source comparison
Cognitive Pathways and Research Protocols: Selank vs Semax Compared
When evaluating Selank vs Semax for cognitive research, the distinction comes down to mechanism and target population. Semax enhances: Attention and processing speed via dopaminergic modulation Working memory through BDNF-driven hippocampal support Neuroprotec
This comparison does not assign a generated winner or score.
- When evaluating Selank vs Semax for cognitive research, the distinction comes down to mechanism and target population.
- Semax enhances:
- Attention and processing speed via dopaminergic modulation
- Working memory through BDNF-driven hippocampal support
- Neuroprotection in ischemic injury models (registered in Russia for stroke and transient ischemic attacks)
- Selank enhances:
- Emotional regulation and stress-impaired cognition
- Anxiety-adjacent cognitive deficits via GABAergic and serotonergic pathways
- Immune-mediated stress responses through cytokine modulation
- A 2020 resting-state fMRI study in 52 healthy participants found that both peptides influence functional connectivity between the right amygdala and temporal cortex — confirming overlapping yet distinct effects on networks governing both anxiety and cognition.
- Primary mechanism
- GABA-A modulation, enkephalin
- BDNF upregulation, dopamine
- Anxiolytic activity
- Strong
- Mild
- Cognitive enhancement
- Stress-impaired focus
- Direct attention/memory
- Neuroimmune activity
- Yes (cytokine regulation)
- Minimal
- Typical research dose
- 200-400 mcg, 2-3x daily
- 300-600 mcg, 1-2x daily
- Approved use (Russia)
- Generalized anxiety disorder
- Ischemic stroke, TIA
- Researchers building multi-pathway stacks may also find value in reviewing what is Selank as a foundational reference before designing protocols.
- For broader neuromodulatory context, the PT-141 neural and metabolic research themes page illustrates how centrally acting peptides can produce overlapping yet mechanistically separate effects — a pattern directly relevant to the Selank vs Semax comparison.
- Combination use of both peptides has been discussed in research circles as a way to address both anxiety and direct cognitive activation simultaneously. However, no controlled Phase 3 trials have evaluated this combination, and caution is warranted until more data emerges. Researchers exploring multi-compound designs may also want to review KLow blend multipathway research for examples of how complementary mechanisms are structured in blended research protocols.
- Both compounds remain unapproved by the FDA, EMA, MHRA, and Health Canada. The majority of published clinical evidence originates from Russian-language journals, limiting direct translation to Western research frameworks.